GSK plc's Nucala (mepolizumab) received approval in China on January 5, 2026, for treating adults with inadequately controlled COPD, marking it as the first monthly biologic for COPD patients in the country. The approval is based on successful trials indicating a significant reduction in exacerbations for patients with a blood eosinophil count as low as 150 cells/µL.